Adjuvant Everolimus Appears Beneficial in Very High-Risk Kidney Cancer
Everolimus improved recurrence-free survival in patients with very high-risk disease but not in those with intermediate high-risk disease.
Renal Cell Carcinoma News
RENAL CELL CARCINOMA ADVISOR
Renal Cell Carcinoma News
Eponyms in Oncology: Von Hippel-Lindau Disease
This weekly series highlights eponyms in oncology. This week, we explore the history and namesakes of von Hippel-Lindau disease.
Robotic Partial Nephrectomy Outcomes Worse When PSMs Are Present
Positive surgical margins in patients undergoing robotic partial nephrectomy for renal tumors are associated with adverse oncologic outcomes, a study revealed.
Neoadjuvant Axitinib May Enable Partial Nephrectomy in Complex Renal Tumors
An interim analysis suggests that axitinib given to patients with complex clear cell renal cell carcinoma tumors significantly reduces tumor size and complexity.
Black vs White Race Tied to Worse Survival in Renal Cell Carcinoma
While socioeconomic disparities are evident, survival differences between racial groups persist after RCC diagnosis.
ICIs May Improve mRCC Outcomes in Cytoreductive Nephrectomy Cases
Immune checkpoint inhibitors may be more beneficial than tyrosine kinase inhibitors for patients undergoing cytoreductive nephrectomy for metastatic renal cell carcinoma.
HRQOL Data Support First-Line Lenvatinib-Pembrolizumab in Advanced Renal Cell Carcinoma
The median time to definitive deterioration was longer with lenvatinib-pembrolizumab than with sunitinib.
DNA Assay May Distinguish Responses to mRCC Immunotherapy
The TARDIS assay could be used to identify appropriate candidates for discontinuation of immune checkpoint inhibitors.
Efficacy, Safety of Triple Combo for Advanced Kidney Cancer Probed
Study provides preliminary data on triple therapy for advanced RCC while clinicians await definitive answers from the ongoing phase 3 COSMIC-313 trial.
Treatment Advances Have Upped Survival in Metastatic Kidney Cancer
Investigators in Austria studied overall survival in 914 patients diagnosed with mRCC from July 1985 to September 2020.
COVID-19 mRNA Vaccine Efficacy Wanes Over Time in RCC Cases
Strategies such as booster doses appear warranted in this population.
Kidney Cancer Metastases Effectively Treated With Robotic Radiosurgery
Investigators examined outcomes of robotic radiosurgery in patients with lung, visceral, and lymph node metastases from renal cell carcinoma.
Lenvatinib+Pembrolizumab Adverse Reactions in Advanced RCC Characterized
Investigators describe the type and frequency of adverse reactions and how clinicians managed them.
Frontline Immunotherapy Appears Effective in mRCC With Poor Performance Status
Patients with poor performance status have been excluded from pivotal trials on metastatic renal cell carcinoma.
Obesity, Hyperglycemia Potentiate Family History’s Effect on Kidney Cancer Risk
Both genetic and lifestyle factors interact to increase the risks for renal cell carcinoma, investigators reported.
Trials Investigating Bempegaldesleukin in Combination With Nivolumab Discontinued
The decision to discontinue the trials was based on data from preplanned analyses of the phase 3 PIVOT-09 study and the phase 2 PIVOT-10 study.
Bevacizumab Biosimilar Alymsys Gets FDA Approval
The approval was based on data demonstrating that the biosimilar product and the reference product were highly similar, and that there were no clinically meaningful differences between the agents.
‘Acceptable’ Long-Term Survival Possible With RN+Thrombectomy for RCC
In a study of patients with RCC and venous thrombus who underwent radical nephrectomy and venous thrombectomy, the median overall survival was 56 months.
Sarcopenia and Inflammation Linked to Worse Survival in mRCC
Patients who had sarcopenia and an elevated neutrophil-to-lymphocyte ratio had the worst overall survival.
High Baseline Troponin T May Predict MACE After Treatment in Renal Cell Carcinoma
Patients who had high baseline troponin T levels had a more than 3-fold greater risk of MACE.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Loading... 
Loading...